AST 1753

Drug Profile

AST 1753

Alternative Names: AST-1753

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator IHM-Labs
  • Developer IHM-Labs; NC-Bio; Wayne State University
  • Class Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Staphylococcal infections
  • No development reported Bacterial endocarditis; Tuberculosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Tuberculosis in Russia (PO, Capsule)
  • 16 Jul 2016 No recent reports of development identified for research development in Bacterial-endocarditis in Russia (PO)
  • 31 Mar 2015 Preclinical trials in Staphylococcal infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top